Sangamo gives another update on early-stage Fabry program, enters trial expansion phase
As Sangamo and Pfizer restart dosing on their Phase III hemophilia A program, Sangamo is also ticking off much earlier-stage benchmarks on its Fabry gene therapy.
At the European Society of Gene and Cell Therapy conference, the Richmond, CA-based biotech posted the latest update on its gene therapy for Fabry disease, a rare X-linked condition in which patients have a mutation in the gene that codes for the alpha-gal enzyme, which is responsible for breaking down fats and sugar. At the last update, which came in late August with a data cutoff of February, Sangamo had data on six patients — and up to that point, it looked like patients were responding to the gene therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.